GenScript Launched GLP-Grade Plasmid DNA Preparation Service
03-Aug-2012 | News-Press Release
Piscataway, N. J., Jul 27, 2012 - GenScript USA Inc., an internationally recognized biology contract research organization (CRO) has launched a new GLP-grade plasmid DNA preparation service.
GenScript’s plasmid preparation service covers individual constructs for research labs as well as large scale manufacturing for biotech and pharmaceutical companies by providing high purity and endotoxin-free plasmids. Through providing DNA plasmids under GLP standards for our in-house downstream services over the past 10 years, such as in DNA-based antibody production, in vivo experiments, and gene therapy studies, GenScript scientists have accumulated a wealth of experience in plasmid DNA preparation.
Good Laboratory Practice (GLP) embodies a set of principles for planning, performing, recording, reporting, and archiving laboratory studies. To meet the needs of pre-clinical downstream applications of the plasmids, GenScript launched the GLP-grade plasmid preparation service. With over 30 SOPs, every single experimental step in the plasmid preparation service has been standardized to guarantee consistent results.
“Our researchers have spent tremendous time and effort to record details of every experimental step and result to warrant the GLP-grade service. Moreover, we have built GLP laboratories designated for the service. The high quality service will pave a smooth path for its downstream applications such as in vivo experiments, DNA-based antibody production, and gene therapy studies”, commented CEO, Frank Zhang.
Founded in 2002, GenScript,has grown together with the synthetic biology industry and is now the world's largest gene synthesis supplier. Headquartered in New Jersey and with subsidiaries in Europe, Japan, and China, GenScript consistently provides the best research services to the scientific community worldwide. Besides the world-leading gene synthesis service, GenScript offers comprehensive services for biological research and early-phase drug discovery, such as bio-reagents, assay development & screening, antibody drug development and research animal model services. Through developing and applying innovative synthetic biology technologies, GenScript assists researchers in advancing and transforming research in biology.
# # # #
For further information, please contact:
Sally Wang
Executive Vice President
GENSCRIPT USA Inc.
sallyw@genscript.com
1-(732) 885-9188
Source: www.genscript.com
Your Innovation Partner in Drug Discovery!
This release was submitted by a PRSafe user.
Any communication related to the content of this release should be sent to the release submitter.
Author Info
Tag Cloud
Categories
More Releases
- GenScript launches a premier gene synthesis service “Gene-BrickTM” for building large DNA fragments
- GenScript Sponsors iGEM – The Largest Competition in Synthetic Biology Field
- GenScript sued GeneWiz for unfair competition